Myriad Genetics Inc.

Organisation

322 North 2200 West, Salt Lake City, UT, United States, 84116

Headquarters

2700

Employees

Health Technology

Industry

R. Bryan Riggsbee

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Price

Target

Myriad Genetics Inc. (MYGN) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Myriad Genetics Inc. (MYGN) share price will touch around $7.78 in next 12-months.

Currently 18 wall-street analysts regularly analyze the financials of Myriad Genetics Inc. on a frequent basis to provide recommendations along with target share price. 18 analysts offering 12-month price forecasts for Myriad Genetics Inc. (MYGN) have a share price target of $7.78. This median of share price forecast represents a 54.06% upside from the latest price of $5.05 as on 13.03.26.

Myriad Genetics Inc. (MYGN) Share Price Forecast

Home

US Stocks

Myriad Genetics Inc. (MYGN)

Myriad Genetics Inc. Stock Forecast

Myriad Genetics Inc. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Myriad Genetics Inc. (MYGN): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Myriad Genetics Inc.'s share price and its median forecast price. As on 13.03.26, the difference is -17.14%

Myriad Genetics Inc. Forecast and Target Price

Myriad Genetics Inc. (MYGN) Share Price Forecast

Myriad Genetics Inc. (MYGN) Price vs Consensus Price Target

Myriad Genetics Inc. (MYGN) Share Price Forecast v/s Share Price Today

Myriad Genetics Inc. (MYGN): Difference between Current Price & Median Forecasted Price

Myriad Genetics Inc. (MYGN) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price